Low-dose meloxicam approved for OA


A low-dose formulation of meloxicam for the treatment of osteoarthritis pain has been approved by the FDA. The medication marketed in the US as Vivlodex by Iroko pharmaceuticals is made using a proprietary technology for producing submicron-size particles of meloxicam that are 10 times smaller than their traditional size. According to company information the reduction ...


Already a member? Login to keep reading


OR
© 2017 the limbic